Skip to main content
Publications
Moehler M, Wyrwicz L, Chen C, Davenport E, Wang J, Nathani R, Kondo K, Elimova E. Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) vs (C). Poster presented at the 2024 German Cancer Congress (Deutscher Krebskongress); February 21, 2024. Berlin, Germany. [abstract] Oncol Res Treat. 2024; 41(Supple 1):65. Previously presented at the 2023 ASCO Annual Meeting.
Law EH, Galve-Calvo E, Wockel A, Parikh R, Kurosky SK, Derrien Ansquer V, Frugier G, Davis KL, Esterberg E, Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04
Todenhofer T, Fizazi K, Shore ND, Tammela T, Kuss I, Le Barre M-A, Mohammed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC). Poster presented at the 2020 German Cancer Congress; February 2020. [abstract] Oncol Res Treat. 2020 Feb; 43(Suppl 1):154-5. Previously presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
Walley D, Twiss J, Doward L, Balp MM, Brass C, Loeffler J, Lopez P, Cai J, Cryer D, Anstee Q, Sanyal A. Patient-reported symptoms and impact in nonalcoholic steatohepatitis: an evaluation of the NASH-CHECK, a novel PROM in NASH. Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. Digital. [abstract] J Hepatol. 2020 Jan; 73:S422-3. doi: 10.1016/S0168-8278(20)33053-1
Breckons M, Doward L, McSweeney L, Balp MM, Twiss J, Oluboyede Y, Vale L, Ternent L, Brass C, Sanyal A, Anstee Q. Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis. Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. digital. [abstract] J Hepatol. 2020 Jan; 73:S423. doi: 10.1016/S0168-8278(20)33053-1
Doward L, Balp MM, Twiss J, Slota C, Cryer D, Langford A, Collen R, Agashivala N, Brass C, Anstee QM, Sanyal A. Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis. Poster presented at the 2018 EASL International Liver Conference; April 13, 2018. Paris, France. [abstract] J Hepatol. 2018 Apr; 68(Suppl 1):S570.
Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD. Understanding factors associated with uptake of BRCA genetic testing among Orthodox Jewish women using a mixed-methods approach. Poster presented at the 2017 San Antonio Breast Cancer Symposium; December 2017. San Antonio, TX. [abstract] Cancer Res. 2018 Feb; 78(4 Suppl).
Doward LC, Balp MM, Stewart KE, Cryer D, Langford A, Twiss J, Agashivala N, Brass C, Anstee QM, Sanyal A. Exploring the patient perceived impact of non-alcoholic steatohepatitis. Poster presented at the 2017 EASL International Liver Conference; April 2017. Amsterdam, The Netherlands. [abstract] J Hepatol. 2017 Apr; 66(1 Supplement):S422-3. doi: 10.1016/S0168-8278(17)31208-4
Ali-Shaw T, Ueng WA, Trivedi MS, Yi H, David RR, Vanegas A, Vargas JM, Sandoval R, Wood J, Kukafka R, Crew KD. Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 2016. San Antonio, TX. [abstract] Cancer Res. 2017 Feb; 77(4_Suppl). doi: 10.1158/1538-7445.SABCS16-P5-10-01
Ueng W, McGuinness J, Infante K, Trivedi MS, Yi HS, David R, Vanegas A, Vargas J, Sandoval R, Kukafka R, Crew KD. Factors associated with false positive results on screening mammography in a population of predominantly Hispanic women. Poster presented at the 107th Annual Meeting of the American Association for Cancer Research; April 2016. New Orleans, LA. [abstract] Cancer Res. 2016 Jul; 76(14_Suppl). doi: 10.1158/1538-7445.AM2016-1790
Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN, Chenevix-Trench G, Webb PM, Beesley J, Chen X, Phelan C, Sutphen R, Sellers TA, Pearce L, Wu AH, Den Berg DV, Conti D, Elund CK, Anderson R, Goodman MT, Lurie G, Carney ME, Thompson PJ, Gayther SA, Ramus SJ, Jacobs I, Kjaer SK, Hogdall E, Blaakaer J, Hogdall C, Easton DF, Song H, Pharoah HDP, Whittemore AS, McGuire V, Quaye L, Anton-Culver H, Ziogas A, Terry KL, Cramer DW, Hankinson SE, Tworoger SS, Calingaert B, Chanock S, Sherman M, Garcia-Closas M. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009 Mar;69(6):2349-57.
David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, Day A, Stumpff J, Hutchison K, Murphy M, Johnstone E, Griffiths SE, Walton RT. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res. 2003 Dec 1;5(6):935-42.